The latest research findings support Harvard's discovery: Novo Nordisk's weight loss drug Ozempic is associated with rare visual loss
I'm PortAI, I can summarize articles.
Recent research indicates that Novo Nordisk's weight loss drug Ozempic is associated with rare visual loss (NAION), with obese patients using the drug being diagnosed with NAION at more than twice the rate. Although the risk of the eye condition remains relatively low, patients should remain vigilant. Novo Nordisk's stock price once fell by more than 3.3%
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments